Peripheral blood lymphocytes subtypes as new predictors for neoadjuvant therapy efficacy in breast cancer
Abstract Background Host immunity plays an important role in tumor development and treatment. Tumor‐infiltrating lymphocytes (TILs) have been proven to predict the efficacy of neoadjuvant therapy (NAT) in breast cancer (BC) patients, but their application is limited due to various reasons. This stud...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-08-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.4666 |
| _version_ | 1828324061979082752 |
|---|---|
| author | Jikun Feng Jiarong Yi Xiazi Zouxu Jianxia Li Zhenchong Xiong Xinjian Huang Wenjing Zhong Weiling Huang Feng Ye Xi Wang |
| author_facet | Jikun Feng Jiarong Yi Xiazi Zouxu Jianxia Li Zhenchong Xiong Xinjian Huang Wenjing Zhong Weiling Huang Feng Ye Xi Wang |
| author_sort | Jikun Feng |
| collection | DOAJ |
| description | Abstract Background Host immunity plays an important role in tumor development and treatment. Tumor‐infiltrating lymphocytes (TILs) have been proven to predict the efficacy of neoadjuvant therapy (NAT) in breast cancer (BC) patients, but their application is limited due to various reasons. This study aims to explore the relationship between peripheral blood lymphocytes (PBLs) subsets distribution and the efficacy of NAT. Methods Between December 2017 and March 2021, a total of 116 BC patients appropriate for NAT in Sun Yat‐Sen University cancer center were enrolled, pre‐NAC baseline blood samples were taken for further flow cytometry analysis to quantitatively evaluate the PBLs subsets distribution, and corresponding clinical information including pathological complete response (pCR) rate of NAT response were recorded. Results Baseline CD3+ T cells(OR 1.11, 1.03–1.21, p = 0.011), CD8+ T cells (OR 1.09, 1.02–1.18, p = 0.015), and NK cells (OR 0.91, 0.83–0.98, p = 0.028) in PBLs subgroup distribution were independent predictors of pCR in BC patients receiving NAT, in which CD8+ T cells had the highest predictive ability (AUC = 0.76). Compared with some previous prediction indicators, its prediction ability has been improved to some extent. Conclusion Peripheral baseline CD3+ T cells, CD8+ T cells, and NK cells were independent predictors of pCR in BC patients receiving NAT, in which CD8+ T cells had the highest predictive ability. Therefore, it can provide newly non‐invasive, relatively accurate and easily accessible predictors for corresponding patients, and help clinicians better understand tumor immunity. |
| first_indexed | 2024-04-13T19:00:30Z |
| format | Article |
| id | doaj.art-9c2ab08385634c608eb630fc7891051c |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-13T19:00:30Z |
| publishDate | 2022-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-9c2ab08385634c608eb630fc7891051c2022-12-22T02:34:06ZengWileyCancer Medicine2045-76342022-08-0111152923293310.1002/cam4.4666Peripheral blood lymphocytes subtypes as new predictors for neoadjuvant therapy efficacy in breast cancerJikun Feng0Jiarong Yi1Xiazi Zouxu2Jianxia Li3Zhenchong Xiong4Xinjian Huang5Wenjing Zhong6Weiling Huang7Feng Ye8Xi Wang9Department of Breast Oncology, Sun Yat‐sen University Cancer Center, the State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong ChinaDepartment of Breast Oncology, Sun Yat‐sen University Cancer Center, the State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong ChinaDepartment of Breast Oncology, Sun Yat‐sen University Cancer Center, the State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong ChinaDepartment of Medical Oncology, The Sixth Affiliated Hospital of Sun Yat‐sen University Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases Guangzhou ChinaDepartment of Breast Oncology, Sun Yat‐sen University Cancer Center, the State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong ChinaDepartment of Breast Oncology, Sun Yat‐sen University Cancer Center, the State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong ChinaDepartment of Breast Oncology, Sun Yat‐sen University Cancer Center, the State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong ChinaDepartment of Breast Oncology, Sun Yat‐sen University Cancer Center, the State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong ChinaDepartment of Breast Oncology, Sun Yat‐sen University Cancer Center, the State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong ChinaDepartment of Breast Oncology, Sun Yat‐sen University Cancer Center, the State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou Guangdong ChinaAbstract Background Host immunity plays an important role in tumor development and treatment. Tumor‐infiltrating lymphocytes (TILs) have been proven to predict the efficacy of neoadjuvant therapy (NAT) in breast cancer (BC) patients, but their application is limited due to various reasons. This study aims to explore the relationship between peripheral blood lymphocytes (PBLs) subsets distribution and the efficacy of NAT. Methods Between December 2017 and March 2021, a total of 116 BC patients appropriate for NAT in Sun Yat‐Sen University cancer center were enrolled, pre‐NAC baseline blood samples were taken for further flow cytometry analysis to quantitatively evaluate the PBLs subsets distribution, and corresponding clinical information including pathological complete response (pCR) rate of NAT response were recorded. Results Baseline CD3+ T cells(OR 1.11, 1.03–1.21, p = 0.011), CD8+ T cells (OR 1.09, 1.02–1.18, p = 0.015), and NK cells (OR 0.91, 0.83–0.98, p = 0.028) in PBLs subgroup distribution were independent predictors of pCR in BC patients receiving NAT, in which CD8+ T cells had the highest predictive ability (AUC = 0.76). Compared with some previous prediction indicators, its prediction ability has been improved to some extent. Conclusion Peripheral baseline CD3+ T cells, CD8+ T cells, and NK cells were independent predictors of pCR in BC patients receiving NAT, in which CD8+ T cells had the highest predictive ability. Therefore, it can provide newly non‐invasive, relatively accurate and easily accessible predictors for corresponding patients, and help clinicians better understand tumor immunity.https://doi.org/10.1002/cam4.4666breast cancerindependent predictorsneoadjuvant therapyPBLs subtypes |
| spellingShingle | Jikun Feng Jiarong Yi Xiazi Zouxu Jianxia Li Zhenchong Xiong Xinjian Huang Wenjing Zhong Weiling Huang Feng Ye Xi Wang Peripheral blood lymphocytes subtypes as new predictors for neoadjuvant therapy efficacy in breast cancer Cancer Medicine breast cancer independent predictors neoadjuvant therapy PBLs subtypes |
| title | Peripheral blood lymphocytes subtypes as new predictors for neoadjuvant therapy efficacy in breast cancer |
| title_full | Peripheral blood lymphocytes subtypes as new predictors for neoadjuvant therapy efficacy in breast cancer |
| title_fullStr | Peripheral blood lymphocytes subtypes as new predictors for neoadjuvant therapy efficacy in breast cancer |
| title_full_unstemmed | Peripheral blood lymphocytes subtypes as new predictors for neoadjuvant therapy efficacy in breast cancer |
| title_short | Peripheral blood lymphocytes subtypes as new predictors for neoadjuvant therapy efficacy in breast cancer |
| title_sort | peripheral blood lymphocytes subtypes as new predictors for neoadjuvant therapy efficacy in breast cancer |
| topic | breast cancer independent predictors neoadjuvant therapy PBLs subtypes |
| url | https://doi.org/10.1002/cam4.4666 |
| work_keys_str_mv | AT jikunfeng peripheralbloodlymphocytessubtypesasnewpredictorsforneoadjuvanttherapyefficacyinbreastcancer AT jiarongyi peripheralbloodlymphocytessubtypesasnewpredictorsforneoadjuvanttherapyefficacyinbreastcancer AT xiazizouxu peripheralbloodlymphocytessubtypesasnewpredictorsforneoadjuvanttherapyefficacyinbreastcancer AT jianxiali peripheralbloodlymphocytessubtypesasnewpredictorsforneoadjuvanttherapyefficacyinbreastcancer AT zhenchongxiong peripheralbloodlymphocytessubtypesasnewpredictorsforneoadjuvanttherapyefficacyinbreastcancer AT xinjianhuang peripheralbloodlymphocytessubtypesasnewpredictorsforneoadjuvanttherapyefficacyinbreastcancer AT wenjingzhong peripheralbloodlymphocytessubtypesasnewpredictorsforneoadjuvanttherapyefficacyinbreastcancer AT weilinghuang peripheralbloodlymphocytessubtypesasnewpredictorsforneoadjuvanttherapyefficacyinbreastcancer AT fengye peripheralbloodlymphocytessubtypesasnewpredictorsforneoadjuvanttherapyefficacyinbreastcancer AT xiwang peripheralbloodlymphocytessubtypesasnewpredictorsforneoadjuvanttherapyefficacyinbreastcancer |